NASDAQ:ATRA Atara Biotherapeutics (ATRA) Stock Price, News & Analysis $10.17 +0.41 (+4.20%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.67▼$10.1850-Day Range$7.30▼$17.7552-Week Range$4.96▼$63.38Volume30,440 shsAverage Volume95,650 shsMarket Capitalization$49.02 millionP/E RatioN/ADividend YieldN/APrice Target$355.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Atara Biotherapeutics alerts: Email Address Atara Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingReduce1.75 Rating ScoreUpside/Downside3,395.6% Upside$355.50 Price TargetShort InterestHealthy13.40% of Float Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.62Based on 2 Articles This WeekInsider TradingSelling Shares$94,860 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($15.75) to ($18.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.78 out of 5 starsMedical Sector229th out of 936 stocksBiological Products, Except Diagnostic Industry30th out of 154 stocks 2.9 Analyst's Opinion Consensus RatingAtara Biotherapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageAtara Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Atara Biotherapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted13.40% of the float of Atara Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverAtara Biotherapeutics has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Atara Biotherapeutics has recently decreased by 6.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAtara Biotherapeutics has received a 75.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Atara Biotherapeutics is -0.87. Previous Next 2.0 News and Social Media Coverage News SentimentAtara Biotherapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Atara Biotherapeutics this week, compared to 2 articles on an average week.Search Interest9 people have searched for ATRA on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Atara Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $94,860.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of Atara Biotherapeutics is held by insiders.Percentage Held by Institutions70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atara Biotherapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Atara Biotherapeutics are expected to decrease in the coming year, from ($15.75) to ($18.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atara Biotherapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atara Biotherapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Atara Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Atara Biotherapeutics Stock (NASDAQ:ATRA)Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.Read More ATRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRA Stock News HeadlinesJuly 19, 2024 | markets.businessinsider.comAtara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial OutlookJuly 19, 2024 | msn.comAtara lead asset tab-cel undergoes FDA priority reviewJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.July 19, 2024 | americanbankingnews.comAnalysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Target Price at $700.00July 18, 2024 | americanbankingnews.comAtara Biotherapeutics (NASDAQ:ATRA) Price Target Lowered to $11.00 at The Goldman Sachs GroupJuly 5, 2024 | businesswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 3, 2024 | businesswire.comAtara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy ForumJune 21, 2024 | businesswire.comAtara Biotherapeutics' Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare DiseasesJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.June 17, 2024 | businesswire.comAtara Biotherapeutics Announces 1-for-25 Reverse Stock SplitJune 7, 2024 | businesswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 5, 2024 | businesswire.comAtara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 29, 2024 | businesswire.comAtara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual MeetingMay 20, 2024 | finance.yahoo.comAtara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares RiseMay 20, 2024 | businesswire.comAtara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDAMay 11, 2024 | finance.yahoo.comAtara Biotherapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Atara Biotherapeutics on Strong Pipeline and Financial HealthMay 10, 2024 | investorplace.comATRA Stock Earnings: Atara Biotherapeutics Beats EPS, Beats Revenue for Q1 2024See More Headlines Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATRA CUSIPN/A CIK1604464 Webwww.atarabio.com Phone(805) 623-4211FaxN/AEmployees330Year FoundedN/APrice Target and Rating Average Stock Price Target$355.50 High Stock Price Target$700.00 Low Stock Price Target$11.00 Potential Upside/Downside+3,542.4%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($53.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-276,130,000.00 Net Margins-671.70% Pretax Margin-671.65% Return on EquityN/A Return on Assets-121.73% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.50 Sales & Book Value Annual Sales$8.57 million Price / Sales5.49 Cash FlowN/A Price / Cash FlowN/A Book Value($24.34) per share Price / Book-0.40Miscellaneous Outstanding Shares4,820,000Free Float4,639,000Market Cap$47.04 million OptionableOptionable Beta0.52 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Pascal Touchon D.V.M. (Age 61)President, CEO & Director Comp: $1.08MMr. K. Amar Murugan (Age 48)Executive VP & Chief Legal Officer Comp: $618.52kMr. Eric Hyllengren (Age 48)Executive VP & Chief Financial Officer Dr. Anhco Nguyen Ph.D. (Age 51)Executive VP and Chief Scientific & Technical Officer Alex ChapmanVice President of Corporate Communications & Investor RelationsMs. Jill Henrich (Age 61)Executive VP and Global Head of Regulatory Affairs & Quality Mr. Dan MaziaszExecutive VP & Chief Business OfficerMs. Rajani Dinavahi M.D.Senior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsCortexymeNASDAQ:CRTXSangamo TherapeuticsNASDAQ:SGMOXBiotechNASDAQ:XBITCoherus BioSciencesNASDAQ:CHRSOrganigramNASDAQ:OGIView All CompetitorsInsiders & InstitutionsRedmile Group LLCBought 156,863 shares on 5/16/2024Ownership: 7.693%Pascal TouchonSold 3,260 sharesTotal: $50,530.00 ($15.50/share)Anhco NguyenSold 1,715 sharesTotal: $26,582.50 ($15.50/share)Eric J HyllengrenSold 1,145 sharesTotal: $17,747.50 ($15.50/share)Price T Rowe Associates Inc. MDBought 4,903,159 shares on 5/15/2024Ownership: 4.117%View All Insider TransactionsView All Institutional Transactions ATRA Stock Analysis - Frequently Asked Questions How have ATRA shares performed this year? Atara Biotherapeutics' stock was trading at $12.82 at the beginning of 2024. Since then, ATRA stock has decreased by 20.7% and is now trading at $10.17. View the best growth stocks for 2024 here. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics, Inc. (NASDAQ:ATRA) posted its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($5.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($9.25) by $3.50. The biotechnology company had revenue of $27.36 million for the quarter, compared to the consensus estimate of $27 million. When did Atara Biotherapeutics' stock split? Atara Biotherapeutics shares reverse split on Thursday, June 20th 2024. The 1-25 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO? 38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend. How do I buy shares of Atara Biotherapeutics? Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and OPKO Health (OPK). This page (NASDAQ:ATRA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATRA Stock Alerts